Search

Your search keyword '"Yuzawa, Yukio"' showing total 900 results
Start Over Author "Yuzawa, Yukio"
900 results on '"Yuzawa, Yukio"'

161. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies

Author

Watanabe, Haruki, primary, Sada, Ken-Ei, additional, Matsumoto, Yoshinori, additional, Harigai, Masayoshi, additional, Amano, Koichi, additional, Fujimoto, Shouichi, additional, Dobashi, Hiroaki, additional, Yuzawa, Yukio, additional, Yamagata, Kunihiro, additional, Muso, Eri, additional, Arimura, Yoshihiro, additional, and Makino, Hirofumi, additional

Published
2020
Full Text
View/download PDF

162. Extreme hyperuricemia is a risk factor for infection-related deaths in incident dialysis patients: a multicenter prospective cohort study

Author

Yoshida, Hiroyuki, primary, Inaguma, Daijo, additional, Koshi-Ito, Eri, additional, Ogata, Soshiro, additional, Kitagawa, Akimitsu, additional, Takahashi, Kazuo, additional, Koide, Shigehisa, additional, Hayashi, Hiroki, additional, Hasegawa, Midori, additional, Yuzawa, Yukio, additional, and Tsuboi, Naotake, additional

Published
2020
Full Text
View/download PDF

166. Prediction model for cardiovascular events or all-cause mortality in incident dialysis patients

Author

Inaguma, Daijo, primary, Morii, Daichi, additional, Kabata, Daijiro, additional, Yoshida, Hiroyuki, additional, Tanaka, Akihito, additional, Koshi-Ito, Eri, additional, Takahashi, Kazuo, additional, Hayashi, Hiroki, additional, Koide, Shigehisa, additional, Tsuboi, Naotake, additional, Hasegawa, Midori, additional, Shintani, Ayumi, additional, and Yuzawa, Yukio, additional

Published
2019
Full Text
View/download PDF

167. Artificial intelligence predicts the progression of diabetic kidney disease using big data machine learning

Author

Makino, Masaki, primary, Yoshimoto, Ryo, additional, Ono, Masaki, additional, Itoko, Toshinari, additional, Katsuki, Takayuki, additional, Koseki, Akira, additional, Kudo, Michiharu, additional, Haida, Kyoichi, additional, Kuroda, Jun, additional, Yanagiya, Ryosuke, additional, Saitoh, Eiichi, additional, Hoshinaga, Kiyotaka, additional, Yuzawa, Yukio, additional, and Suzuki, Atsushi, additional

Published
2019
Full Text
View/download PDF

168. Influx of Tau and Amyloid-β Proteins into the Blood During Hemodialysis as a Therapeutic Extracorporeal Blood Amyloid-β Removal System for Alzheimer’s Disease

Author

Kitaguchi, Nobuya, primary, Tatebe, Harutsugu, additional, Sakai, Kazuyoshi, additional, Kawaguchi, Kazunori, additional, Matsunaga, Shinji, additional, Kitajima, Tomoko, additional, Tomizawa, Hiroshi, additional, Kato, Masao, additional, Sugiyama, Satoshi, additional, Suzuki, Nobuo, additional, Mizuno, Masao, additional, Takechi, Hajime, additional, Nakai, Shigeru, additional, Hiki, Yoshiyuki, additional, Kushimoto, Hiroko, additional, Hasegawa, Midori, additional, Yuzawa, Yukio, additional, and Tokuda, Takahiko, additional

Published
2019
Full Text
View/download PDF

172. Comparison Between the Internal and External Pressure Filtration Method of Cell‐Free and Concentrated Ascites Reinfusion Therapy Using the Same Cancerous Ascites

Author

Yamada, Sachie, primary, Hasegawa, Midori, additional, Nii, Norio, additional, Kato, Masao, additional, Ohashi, Atsushi, additional, Suzuki, Ryota, additional, Komatsu, Masakazu, additional, Abe, Kosei, additional, Hata, Yosuke, additional, Takahashi, Kazuo, additional, Hayashi, Hiroki, additional, Koide, Shigehisa, additional, Tsuboi, Naotake, additional, Inaguma, Daijo, additional, and Yuzawa, Yukio, additional

Published
2019
Full Text
View/download PDF

174. Clinical impact of urinary CD11b and CD163 on the renal outcomes of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Author

Yokoe, Yuki, Tsuboi, Naotake, Imaizumi, Takahiro, Kitagawa, Akimitsu, Karasawa, Munetoshi, Ozeki, Takaya, Endo, Nobuhide, Sawa, Yuriko, Kato, Sawako, Katsuno, Takayuki, Maruyama, Shoichi, Yamagata, Kunihiro, Usui, Joichi, Nagata, Michio, Sada, Ken-Ei, Sugiyama, Hitoshi, Amano, Koichi, Arimura, Yoshihiro, Atsumi, Tatsuya, and Yuzawa, Yukio

Subjects
NEPHRITIS, GLOMERULONEPHRITIS, ENZYME-linked immunosorbent assay, DIAGNOSIS, EPIDERMAL growth factor receptors, LOGISTIC regression analysis
Abstract

Background The detection of leukocyte-derived CD11b (α subunit of integrin Mac-1) and CD163 (scavenger receptor) in urine may reflect renal inflammation in antineutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN). The objective of this study was to evaluate the clinical significance of urinary CD11b (U-CD11b) and CD163 (U-CD163) in ANCA-GN. Methods U-CD11b and U-CD163 were examined using enzyme-linked immunosorbent assay in ANCA-GN urine samples from our institutional cohort (n  = 88) and a nationwide cohort (n  = 138), and their association with renal histology was subsequently analyzed. Logistic regression analyses were performed on a nationwide ANCA cohort to determine the associations of the two urinary molecules with renal remission failure at 6 months or with yearly estimated glomerular filtration rate (eGFR) slope over a 24-month observation period. Results U-CD11b and U-CD163 were significantly associated with cellular crescent formation and leukocyte accumulation in glomerular crescents. With regard to interstitial inflammation, both levels of U-CD11b and U-CD163 at diagnosis remarkably increased in ANCA-GN compared with the levels observed in nonglomerular kidney disorders including nephrosclerosis, immunoglobulin G4-related disease and tubulointerstitial nephritis; however, the presence of U-CD11b alone was significantly correlated with tubulointerstitial leukocyte infiltrates. Although neither U-CD11b nor U-CD163 at diagnosis was associated with remission failure at 6 months, multivariate analysis demonstrated that the baseline U-CD11b levels were significantly associated with the increase in eGFR following immunosuppressive therapy. Conclusions Although both U-CD11b and U-CD163 reflect renal leukocyte accumulation, U-CD11b at diagnosis provides additional clinical value by predicting the recovery rate after the treatment of ANCA-GN. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

178. Reduction of severe acute respiratory syndrome coronavirus‐2 infectivity by admissible concentration of ozone gas and water.

Author

Murata, Takayuki, Komoto, Satoshi, Iwahori, Satoko, Sasaki, Jun, Nishitsuji, Hironori, Hasebe, Terumitsu, Hoshinaga, Kiyotaka, and Yuzawa, Yukio

Subjects
COVID-19, OZONE, SARS-CoV-2, OZONE layer
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is causing the global coronavirus disease 2019 (COVID‐19) pandemic. Because complete elimination of SARS‐CoV‐2 appears difficult, decreasing the risk of transmission is important. Treatment with 0.1 and 0.05 ppm ozone gas for 10 and 20 hr, respectively, decreased SARS‐CoV‐2 infectivity by about 95%. The magnitude of the effect was dependent on humidity. Treatment with 1 and 2 mg/L ozone water for 10 s reduced SARS‐CoV‐2 infectivity by about 2 and 3 logs, respectively. Our results suggest that low‐dose ozone, in the form of gas and water, is effective against SARS‐CoV‐2. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

183. P2‐057: REMOVAL OF Aβ OLIGOMERS FROM THE BLOOD USING HOLLOW FIBERS: A POTENTIAL THERAPEUTIC SYSTEM FOR ALZHEIMER'S DISEASE

Author

Saito, Yuta, primary, Kobayakawa, Moe, additional, Sakata, Miwa, additional, Kawaguchi, Kazunori, additional, Morikawa, Hiroshi Kawachi, additional, Ohashi, Norimi, additional, Hiki, Yoshiyuki, additional, Kato, Masao, additional, Hasegawa, Midori, additional, Yuzawa, Yukio, additional, and Kitaguchi, Nobuya, additional

Published
2018
Full Text
View/download PDF

186. The Japanese Clinical Practice Guideline for acute kidney injury 2016

Author

70378769, Doi, Kent, Nishida, Osamu, Shigematsu, Takashi, Sadahiro, Tomohito, Itami, Noritomo, Iseki, Kunitoshi, Yuzawa, Yukio, Okada, Hirokazu, Koya, Daisuke, Kiyomoto, Hideyasu, Shibagaki, Yugo, Matsuda, Kenichi, Kato, Akihiko, Hayashi, Terumasa, Ogawa, Tomonari, Tsukamoto, Tatsuo, Noiri, Eisei, Negi, Shigeo, Kamei, Koichi, Kitayama, Hirotsugu, Kashihara, Naoki, Moriyama, Toshiki, Terada, Yoshio, Inokuchi, Ryota, Hara, Yoshitaka, Hayashi, Hiroki, Tomori, Koji, Moriguchi, Takeshi, Yamada, Hiroyuki, Yamashita, Tetsushi, Horino, Taro, Mori, Kiyoshi, Taniyama, Yoshihiro, Wakino, Shu, Yasuda, Hideo, Tsuji, Takayuki, Kume, Shinji, Sofue, Tadashi, Fujisaki, Kiichiro, Shima, Hideaki, Watanabe, Yusuke, Yamashita, Kazuto, Nakamura, Kensuke, Furuichi, Kengo, Sasaki, Sho, Yonemoto, Sayoko, Nakada, aki, Taka, Hattori, Noriyuki, Kiuchi, Zentaro, Sawada, Mariko, Takahashi, Masaki, Tani, Masanori, Nakazawa, Yusuke, Nunoyama, Masaki, Fukui, Tsuguya, Matsuo, Seiichi, Maruyama, Shoichi, Yanagita, Motoko, Tsuruya, Kazuhiko, 70378769, Doi, Kent, Nishida, Osamu, Shigematsu, Takashi, Sadahiro, Tomohito, Itami, Noritomo, Iseki, Kunitoshi, Yuzawa, Yukio, Okada, Hirokazu, Koya, Daisuke, Kiyomoto, Hideyasu, Shibagaki, Yugo, Matsuda, Kenichi, Kato, Akihiko, Hayashi, Terumasa, Ogawa, Tomonari, Tsukamoto, Tatsuo, Noiri, Eisei, Negi, Shigeo, Kamei, Koichi, Kitayama, Hirotsugu, Kashihara, Naoki, Moriyama, Toshiki, Terada, Yoshio, Inokuchi, Ryota, Hara, Yoshitaka, Hayashi, Hiroki, Tomori, Koji, Moriguchi, Takeshi, Yamada, Hiroyuki, Yamashita, Tetsushi, Horino, Taro, Mori, Kiyoshi, Taniyama, Yoshihiro, Wakino, Shu, Yasuda, Hideo, Tsuji, Takayuki, Kume, Shinji, Sofue, Tadashi, Fujisaki, Kiichiro, Shima, Hideaki, Watanabe, Yusuke, Yamashita, Kazuto, Nakamura, Kensuke, Furuichi, Kengo, Sasaki, Sho, Yonemoto, Sayoko, Nakada, aki, Taka, Hattori, Noriyuki, Kiuchi, Zentaro, Sawada, Mariko, Takahashi, Masaki, Tani, Masanori, Nakazawa, Yusuke, Nunoyama, Masaki, Fukui, Tsuguya, Matsuo, Seiichi, Maruyama, Shoichi, Yanagita, Motoko, and Tsuruya, Kazuhiko

Abstract

Acute kidney injury (AKI) is a syndrome which has a broad range of etiologic factors depending on different clinical settings. Because AKI has significant impacts on prognosis in any clinical settings, early detection and intervention are necessary to improve the outcomes of AKI patients. This clinical guideline for AKI was developed by a multidisciplinary approach with nephrology, intensive care medicine, blood purification, and pediatrics. Of note, clinical practice for AKI management which was widely performed in Japan was also evaluated with comprehensive literature search.

Published
2018

187. Mass spectrometry-based approach for development of biomarkers in IgA nephropathy: a pilot trial

Author

Kondo, Ayako, Takahashi, Kazuo, Yamaguchi, Hisateru, Yoshida, Yuri, Mizuno, Tomohiro, Nakajima, Kazuki, Hayashi, Hiroki, Koide, Shigehisa, Inaguma, Daijo, Hasegawa, Midori, Hiki, Yoshiyuki, Yuzawa, Yukio, Kondo, Ayako, Takahashi, Kazuo, Yamaguchi, Hisateru, Yoshida, Yuri, Mizuno, Tomohiro, Nakajima, Kazuki, Hayashi, Hiroki, Koide, Shigehisa, Inaguma, Daijo, Hasegawa, Midori, Hiki, Yoshiyuki, and Yuzawa, Yukio

Published
2018

188. Removal of blood amyloid-β with hemodialysis reduced brain amyloid-β, confirmed by brain imaging: a case report

Author

Kitaguchi,Nobuya, Kato,Takashi, Matsunaga,Shinji, Hirano,Kyoko, Iwata,Kaori, Kawaguchi,Kazunori, Fujita,Kiyoshi, Takechi,Hajime, Hasegawa,Midori, Yuzawa,Yukio, Ito,Kengo, Kitaguchi,Nobuya, Kato,Takashi, Matsunaga,Shinji, Hirano,Kyoko, Iwata,Kaori, Kawaguchi,Kazunori, Fujita,Kiyoshi, Takechi,Hajime, Hasegawa,Midori, Yuzawa,Yukio, and Ito,Kengo

Abstract

Nobuya Kitaguchi,1 Takashi Kato,2 Shinji Matsunaga,3 Kyoko Hirano,4 Kaori Iwata,2 Kazunori Kawaguchi,1 Kiyoshi Fujita,5 Hajime Takechi,3 Midori Hasegawa,4 Yukio Yuzawa,4 Kengo Ito21School of Health Sciences, Fujita Health University, Toyoake, Aichi, Japan; 2Department of Brain Science and Molecular Imaging, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan; 3Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 4Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan; 5Okehazama Hospital, Fujita Kokoro Center, Seisinkai, Toyoake, Aichi, JapanAbstract: The accumulation of amyloid-β protein (Aβ) in the brain signifies a major pathological change of Alzheimer’s disease (AD). Extracorporeal blood Aβ removal system (E-BARS) has been under development as a tool for enhancing the clearance of Aβ from the brain. Previously, we revealed that dialyzers remove blood Aβs effectively, evoking substantial Aβ influx into the blood during hemodialysis sessions as one form of blood Aβ removal by E-BARS, and that postmortem brains of hemodialysis patients exhibited lower Aβ accumulation. Here, we present a case report of a 77-year-old male patient with end-stage renal failure whose Aβ accumulation in the brain declined by initiating and continuing hemodialysis for 6 months. This report suggests that blood Aβ removal by E-BARS could be an effective therapeutic method for AD.Keywords: amyloid-β, Aβ, PiB/PET, blood purification, blood Aβ removal, Alzheimer’s disease, E-BARS, extracorporeal blood Aβ removal system

Published
2018

189. Additional file 1: Figure S1. of Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Author

Ishizaki, Jun, Takemori, Ayako, Suemori, Koichiro, Matsumoto, Takuya, Akita, Yoko, Ken-Ei Sada, Yuzawa, Yukio, Amano, Koichi, Takasaki, Yoshinari, Harigai, Masayoshi, Arimura, Yoshihiro, Makino, Hirofumi, Yasukawa, Masaki, Takemori, Nobuaki, and Hasegawa, Hitoshi

Abstract

Screening of marker candidates in serum samples from patients with AAV. Figure S2. Schematic diagram of targeted proteomics using the LC-SRM assay. Figure S3. Correlations between the light/heavy ratio of SRM and the ELISA titers of markers. Figure S4 Correlation of marker levels with total BVAS score of patients with AAV. Table S1. Clinical data on healthy donors and patients with RA, SLE, and infectious diseases. Table S3. Selected marker candidates for SRM assay development. Table S4. A set of established SRM transitions for the detection of marker candidates. Table S5. The 20 proteins with a significant change before and at 6 months after treatment in protocol 1 (n = 23) and protocol 2 (n = 29) in the SRM assay. Table S6. Comparison of serum levels of biomarker candidates between the remission group (n = 62) and the nonremission group (n = 17) at 6 months after treatment. Table S7. Marker levels in old healthy donors. Table S8. Comparison of serum levels of biomarker candidates between the patients with AAV with (n = 120) and without (n = 49) renal involvement before treatment. Table S9. Comparison of serum levels of biomarker candidates between the patients with AAV with and without lung involvement before treatment. Table S10. Comparison of marker levels among MPA, GPA, and EGPA before treatment. Table S11 Association of marker levels with disease severity in patients with AAV before treatment. (PDF 2221 kb)

Published
2017
Full Text
View/download PDF

191. The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases

Author

Mori, Yoshiko, primary, Masuda, Tomohiro, additional, Kosugi, Tomoki, additional, Yoshioka, Tomoki, additional, Hori, Mayuko, additional, Nagaya, Hiroshi, additional, Maeda, Kayaho, additional, Sato, Yuka, additional, Kojima, Hiroshi, additional, Kato, Noritoshi, additional, Ishimoto, Takuji, additional, Katsuno, Takayuki, additional, Yuzawa, Yukio, additional, Kadomatsu, Kenji, additional, and Maruyama, Shoichi, additional

Published
2017
Full Text
View/download PDF

192. Adsorptive filtration systems for effective removal of blood amyloid β: a potential therapy for Alzheimer’s disease

Author

Kitaguchi, Nobuya, primary, Kawaguchi, Kazunori, additional, Yamazaki, Kazunori, additional, Kawachi, Hiroshi, additional, Sakata, Miwa, additional, Kaneko, Megumi, additional, Kato, Masao, additional, Sakai, Kazuyoshi, additional, Ohashi, Norimi, additional, Hasegawa, Midori, additional, Hiki, Yoshiyuki, additional, and Yuzawa, Yukio, additional

Published
2017
Full Text
View/download PDF

193. Combination Therapy with Renin-Angiotensin System Blockers and Vitamin D Receptor Activators for Predialysis Patients Is Associated with the Incidence of Cardiovascular Events after Dialysis Initiation: A Multicenter Nonrandomized Prospective Cohort Study

Author

Inaguma, Daijo, primary, Ito, Eri, additional, Koide, Shigehisa, additional, Takahashi, Kazuo, additional, Hayashi, Hiroki, additional, Hasegawa, Midori, additional, and Yuzawa, Yukio, additional

Published
2017
Full Text
View/download PDF

194. Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia

Author

Wada, Takashi, primary, Muso, Eri, additional, Maruyama, Shoichi, additional, Hara, Akinori, additional, Furuichi, Kengo, additional, Yoshimura, Kenichi, additional, Miyazaki, Mariko, additional, Sato, Eiichi, additional, Abe, Masanori, additional, Shibagaki, Yugo, additional, Narita, Ichiei, additional, Yokoyama, Hitoshi, additional, Mori, Noriko, additional, Yuzawa, Yukio, additional, Matsubara, Takeshi, additional, Tsukamoto, Tatsuo, additional, Wada, Jun, additional, Ito, Takafumi, additional, Masutani, Kosuke, additional, Tsuruya, Kazuhiko, additional, Fujimoto, Shoichi, additional, Tsuda, Akihiro, additional, Suzuki, Hitoshi, additional, Kasuno, Kenji, additional, Terada, Yoshio, additional, Nakata, Takeshi, additional, Iino, Noriaki, additional, and Kobayashi, Shuzo, additional

Published
2017
Full Text
View/download PDF

195. [P2-041]: POTENTIAL THERAPEUTIC SYSTEM FOR ALZHEIMER's DISEASE BY REMOVING BLOOD Aβ: EFFECTS OF BLOOD PURIFICATION PERIOD ON Aβ REMOVAL EFFICIENCIES IN HEMODIALYSIS PATIENTS

Author

Morikawa, Hiroshi, primary, Tomizawa, Hiroshi, additional, Kawaguchi, Kazunori, additional, Suzuki, Nobuo, additional, Ohashi, Norimi, additional, Sakata, Miwa, additional, Mineshima, Michio, additional, Sobajima, Hiroshi, additional, Hasegawa, Midori, additional, Mizuno, Masao, additional, Yuzawa, Yukio, additional, and Kitaguchi, Nobuya, additional

Published
2017
Full Text
View/download PDF

198. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

Author

Trimarchi, Hernán, primary, Barratt, Jonathan, additional, Cattran, Daniel C., additional, Cook, H. Terence, additional, Coppo, Rosanna, additional, Haas, Mark, additional, Liu, Zhi-Hong, additional, Roberts, Ian S.D., additional, Yuzawa, Yukio, additional, Zhang, Hong, additional, Feehally, John, additional, Alpers, Charles E., additional, Asunis, Ana María, additional, Barbour, Sean, additional, Becker, Jan U., additional, Ding, Jie, additional, Espino, Gabriella, additional, Ferrario, Franco, additional, Fogo, Agnes, additional, Hladunewich, Michelle, additional, Joh, Kensuke, additional, Katafuchi, Ritsuko, additional, Lv, Jicheng, additional, Matsuzaki, Keiichi, additional, Nakanishi, Koichi, additional, Pani, Antonello, additional, Perera, Ran, additional, Perkowska-Ptasinska, Agnieszka, additional, Reich, Heather, additional, Shima, Yuko, additional, Soares, Maria Fernanda, additional, Suzuki, Yusuke, additional, Takahashi, Katsuo, additional, Troyanov, Stéphan, additional, Verhave, Jacobien C., additional, Wang, Suxia, additional, Weening, Jan, additional, Wyatt, Robert, additional, Yoshikawa, Nori, additional, and Zeng, Caihong, additional

Published
2017
Full Text
View/download PDF

199. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes

Author

Furuichi, Kengo, primary, Yuzawa, Yukio, additional, Shimizu, Miho, additional, Hara, Akinori, additional, Toyama, Tadashi, additional, Kitamura, Hiroshi, additional, Suzuki, Yoshiki, additional, Sato, Hiroshi, additional, Uesugi, Noriko, additional, Ubara, Yoshifumi, additional, Hisano, Satoshi, additional, Ueda, Yoshihiko, additional, Nishi, Shinichi, additional, Yokoyama, Hitoshi, additional, Nishino, Tomoya, additional, Kohagura, Kentaro, additional, Ogawa, Daisuke, additional, Mise, Koki, additional, Shibagaki, Yugo, additional, Kimura, Kenjiro, additional, Haneda, Masakazu, additional, Makino, Hirofumi, additional, Matsuo, Seiichi, additional, and Wada, Takashi, additional

Published
2017
Full Text
View/download PDF

200. Relationship Between Patterns in Antihypertensive Drugs Medication and Mortality in Incident Dialysis Patients: A Multicenter Prospective Cohort Study.

Author

Fujii, Maya, Inaguma, Daijo, Koide, Shigehisa, Ito, Eri, Takahashi, Kazuo, Hayashi, Hiroki, Tsuboi, Naotake, Hasegawa, Midori, and Yuzawa, Yukio

Subjects
HEMODIALYSIS patients, LONGITUDINAL method, COHORT analysis, CALCIUM antagonists, DRUG prescribing
Abstract

Hypertension is common in patients with chronic kidney disease. Whether blood pressure management before dialysis initiation influences prognosis during maintenance dialysis remains unclear. Hence, we surveyed the status of antihypertensive drug use in incident dialysis patients. Moreover, we examined the association between antihypertensive drug use patterns at the time of dialysis initiation and mortality. We used a database derived from the multicenter prospective Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis, which included 1520 incident dialysis patients in Aichi prefecture, Japan. The baseline in the present study was set as the time of dialysis initiation. We examined antihypertensive drug prescription patterns at baseline, as well as the association between use of antihypertensive drugs and mortality after dialysis initiation. Among all participants, 1440 were taking at least one antihypertensive drug. The rate of calcium channel blocker (CCB) use was highest, accounting for 74.3%. CCB use was significantly associated with lower all‐cause and cardiovascular‐related mortality (hazard ratio [HR]: 0.62 and 0.57, 95% confidence interval [CI]: 0.46–0.85 and [0.35–0.91], respectively). Compared with no use of either drug, combination therapy with a renin angiotensin system blocker (RASB) and CCB was significantly associated with lower mortality (HR: 0.51, 95% CI: 0.34–0.76). The present study demonstrated that antihypertensive drugs were used in 95% of incident dialysis patients. In addition, use of a CCB and combination therapy with a CCB and RASB at the time of dialysis initiation was associated with lower mortality during maintenance dialysis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results